Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dapagliflozin on periprocedural myocardial injury and contrast-induced acute kidney injury
TCTR20230109004Phase 3Unknown
- Sponsor
- National Science, Research and Innovation Fund
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in periprocedural myocardial injury, contrast-induced nephropathy (CIN), sponsored by National Science, Research and Innovation Fund. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
periprocedural myocardial injurycontrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on TCTR20230109004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230109004.